Twist, Snail, Slug. They may sound like words in a children’s nursery rhyme, but they are actually the exotic names given to proteins that can generate cells with stem cell-like properties that have the ability to form diverse types of tissue. One protein with the even more out-there name of ZEB1 (zinc finger E-box binding homeobox 1), is now thought to keep breast cancer cells from being successfully treated with radiation therapy, according to a study at the MD Anderson Cancer Center.
The team state that ZEB1 may actually be helping breast tumour cells repair DNA damage caused by radiation treatment by ramping up a first-line of defense known as DNA damage response pathway. Radiation therapy causes cell death by inducing DNA ‘ breaks’. The rationale for treating tumours with radiation without damaging normal tissues is that, compared with normal cells, tumour cells are actively dividing and often have defects in DNA damage repair machinery.
Tumour cells are thus less able to repair DNA damage. But not always. Sometimes the body produces tumour cells resistant to radiation. They are somehow able to ‘turn on’ the DNA damage response apparatus. Until now, the question has always been how?
The team has demonstrated that the wily tumour cell’s ability to push the panic button at the last second can be triggered by ZEB1’s penchant for launching an operation that generates cancer stem cells.
The cancer stem cells have been shown to promote radioresistance through activation of the DNA damage response system. The studies have shown that ZEB1 can induce a process known as epithelial-mesenchymal transition (EMT) which allows certain tumours to acquire cancer stem cell properties including radioresistance.
EMT is one way the body responds to wound healing and it is believed that cancer has found a method for using EMT to promote tumour progression.
ZEB1 achieves this unfortunate result through a complex chain of events that permit a gene known as ATM to stabilize the protein Chk1 that plays an important role in DNA damage response. ZEB1 promotes Chk1’s ability to allow tumour radioresistance through deployment of an enzyme called USP7.
The hope is that new approaches to addressing radiation resistance may be developed through gaining better insight into how this signalling pathway keeps tumour cells growing despite being bombarded with toxic radiation treatments.
Radiation therapy plays a key role in breast cancer management. To overcome the obstacle of radioresistant tumour cells, it is important to identify the critical causes and to develop safe and effective new methods for treatment including the possible use of agents that target ZEB1 and which inhibit CHK1.
Source: MD Anderson Cancer Center
biomarker, cancer, Chk1, DNA methylation, dna mutation, drug resistance, EMT, epigenetics, healthinnovations, metastasis, Oncology, pithelial-mesenchymal transition, precision medicine, proteome, radioresistance, radiotherapy, stem cell, tumour, ZEB1
Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.
Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation--expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.